JP2007536920A - イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化 - Google Patents

イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化 Download PDF

Info

Publication number
JP2007536920A
JP2007536920A JP2007512116A JP2007512116A JP2007536920A JP 2007536920 A JP2007536920 A JP 2007536920A JP 2007512116 A JP2007512116 A JP 2007512116A JP 2007512116 A JP2007512116 A JP 2007512116A JP 2007536920 A JP2007536920 A JP 2007536920A
Authority
JP
Japan
Prior art keywords
expression
mammal
responsive
pdgf receptor
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007512116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536920A5 (enExample
Inventor
モニカ・ニスター
ダニエル・ヘーゲッシュトランド
イェーラン・ヘッセラガー
アルネ・オストマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UPPSALA UNIVERSITY HOSPITAL
Ludwig Institute for Cancer Research Ltd
Original Assignee
UPPSALA UNIVERSITY HOSPITAL
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0410883A external-priority patent/GB0410883D0/en
Priority claimed from GB0425257A external-priority patent/GB0425257D0/en
Application filed by UPPSALA UNIVERSITY HOSPITAL, Ludwig Institute for Cancer Research Ltd filed Critical UPPSALA UNIVERSITY HOSPITAL
Publication of JP2007536920A publication Critical patent/JP2007536920A/ja
Publication of JP2007536920A5 publication Critical patent/JP2007536920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2007512116A 2004-05-14 2005-05-13 イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化 Pending JP2007536920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0410883A GB0410883D0 (en) 2004-05-14 2004-05-14 Organic compounds
GB0425257A GB0425257D0 (en) 2004-11-16 2004-11-16 Organic compounds
PCT/EP2005/005269 WO2005113801A2 (en) 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib

Publications (2)

Publication Number Publication Date
JP2007536920A true JP2007536920A (ja) 2007-12-20
JP2007536920A5 JP2007536920A5 (enExample) 2008-07-03

Family

ID=35295424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007512116A Pending JP2007536920A (ja) 2004-05-14 2005-05-13 イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化

Country Status (9)

Country Link
US (1) US20080199855A1 (enExample)
EP (1) EP1756306A2 (enExample)
JP (1) JP2007536920A (enExample)
AU (1) AU2005245572B9 (enExample)
BR (1) BRPI0511088A (enExample)
CA (1) CA2564654A1 (enExample)
MX (1) MXPA06013079A (enExample)
RU (1) RU2006144122A (enExample)
WO (1) WO2005113801A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016136938A (ja) * 2009-08-25 2016-08-04 バーグ エルエルシー エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132336A1 (en) * 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
EA201691257A1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2004000018A (ja) * 2002-05-22 2004-01-08 Univ Tokyo イマチニブに対する感受性の判定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829154B1 (fr) * 2001-09-05 2003-10-17 Assist Publ Hopitaux De Paris Nouveau procede de detection d'une mutation en phase de lecture dans une sequence codante et appareil pour sa mise en oeuvre

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2004000018A (ja) * 2002-05-22 2004-01-08 Univ Tokyo イマチニブに対する感受性の判定方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016136938A (ja) * 2009-08-25 2016-08-04 バーグ エルエルシー エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法

Also Published As

Publication number Publication date
AU2005245572B9 (en) 2009-01-29
RU2006144122A (ru) 2008-06-20
CA2564654A1 (en) 2005-12-01
MXPA06013079A (es) 2007-10-08
US20080199855A1 (en) 2008-08-21
AU2005245572B2 (en) 2008-12-04
AU2005245572A1 (en) 2005-12-01
EP1756306A2 (en) 2007-02-28
BRPI0511088A (pt) 2007-12-26
WO2005113801A2 (en) 2005-12-01
WO2005113801A3 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
US20240124937A1 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
JP7037836B2 (ja) タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途
JP2009523410A (ja) 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
Vasilev et al. Clinical and molecular update on genetic causes of pituitary adenomas
JP2016515380A (ja) 肺癌の分類及び実施可能性インデックス
JP2009505658A (ja) 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
RU2663701C2 (ru) Маркеры, ассоциированные с ингибиторами wnt
JP2004000018A (ja) イマチニブに対する感受性の判定方法
CN101512017A (zh) 评价用靶向ret受体酪氨酸激酶的药物治疗的患者的方法
JP6387001B2 (ja) Ｃｄｋ阻害剤と関連するバイオマーカー
US20150080239A1 (en) Classification and Actionability Indices for Cancer
EP1759010A2 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP2007536920A (ja) イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化
Lee et al. ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip
JP2005529582A (ja) 肝臓疾患における遺伝子発現プロファイル
CN1997755A (zh) 对伊马替尼治疗敏感的胶质母细胞瘤亚群的鉴定和表征
JP2005034151A (ja) 癌を評価および治療する方法
KR20070031902A (ko) 이매티닙을 사용하는 치료에 대하여 감수성인아교모세포종의 서브세트의 확인 및 특성화
JP2011505807A (ja) キナゾリノン化合物による治療をモニタリングするためのバイオマーカー
Navarro Cerveró et al. Identification of new genetic clusters in glioblastoma multiforme: EGFR status and ADD3 losses Influence prognosis.
HK1243138B (zh) Il-33介导型疾病的治疗方法和诊断方法
HK1243138A1 (en) Therapeutic and diagnostic methods for il-33-mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110920